Antineoplastons (Burzynski)

Domain XII · Complementary, energy & biofield · Stanislaw R. Burzynski · 1976 · United States

What it is

Who, where, when. Antineoplastons are a group of compounds that Burzynski began developing while in medical school in Poland in the 1960s; he left a laboratory post at Baylor College of Medicine in 1977, opened a Houston laboratory and began private practice using them. NCI dates the first proposal…

Format

• Who, where, when. Antineoplastons are a group of compounds that Burzynski began developing while in medical school in Poland in the 1960s; he left a laboratory post at Baylor College of Medicine in 1977, opened a Houston laboratory and began private practice using them. NCI dates the first proposal…
• Stated rationale (as the developer framed it). Burzynski proposed, drawing on cybernetic information theory, that the body has a natural biochemical "surveillance" system of peptides that signal cells to differentiate normally, that people with cancer lack these peptides, and that replacing them…

Who practises it, and how they are trained or regulated

• The sequence below is assembled from regulatory, court and press sources; individual patients' courses varied, and details that sources did not report are marked.
• Selection and "enrolment". Patients were enrolled in one of the clinic's FDA-registered studies or treated under expanded (individual) access, because the 1998 judgment allowed antineoplastons only within FDA-approved trials. FDA inspectors found the clinic repeatedly failed to ensure patients had a required waiting period after earlier treatment before starting the new one.
• Regulatory and evidence status (one line each). Regulatory: "not approved by the U.S. Food and Drug Administration for the prevention or treatment of any disease". Evidence: no randomised controlled trial showing effectiveness has been published in the peer-reviewed literature, and no phase III trial has been conducted; most human reports are case reports and phase I or toxicity studies by the developer, often…

Evidence status, as the guide reports it

• "Clinical trials" as the access route. After state litigation, a 1998 final judgment restricted Burzynski to giving antineoplastons only to patients in FDA-approved clinical trials (unless the FDA approved the drug) and required his advertising to state that safety and effectiveness had not been…

Questions to explore with your client

• What drew you to it, and what are you hoping it will change?
• Does it involve any substance, plant preparation, remedy or supplement? Has your doctor or prescriber been told, especially about any medication you take?
• Does it involve fasting, a special diet or 'detox'? Have you discussed this with your doctor?
• Is it a group, retreat or community? How do they respond if someone wants to leave or raises a concern?
• Does it use a device, heat, cold, water or a physical procedure? Has a medical professional checked that it is safe for you?
• Who runs it, and what training or registration do they hold?
• What actually happens in a session or meeting, and how often?
• What does it cost, and is there pressure to commit to more?
• How do you feel afterwards, in the hours and days that follow?
• Does it fit with, or clash with, the work we do here?

What practitioners of it watch for

• Avoidance of medical follow-up; re-engagement with another unproven regime. Working: return to routine medical care.
• Splitting, ultimatums, a relative cutting off contact. Working: the patient's voice is heard and disagreements are spoken rather than acted out.
• The client hiding the regime from the team; the team withdrawing from the client — advocate for continued palliative care. Working: one shared plan.
• Self-blame, anger turned on medical staff or on the family member who disagreed, hopelessness. Working: the client can hold love and regret together.
• Fear of legal retaliation (the clinic threatened critics with legal action); suggest legal advice. Working: the client decides with full information.

Problems the guide addresses

• Asking without judgement and exploring meaning
• Autonomy-respecting decision support (adults)
• Coordination with treating physicians, oncology and palliative teams
• Children: consent, assent and safeguarding
• Financial harm and fundraising pressure
• Supporting a client currently on the regime
• Grief, regret and guilt after the choice
• Family conflict
• Assessment and treatment after going through it
• Reporting and documentation

When to involve someone else

• New or worsening physical symptoms, or advice to stop or change prescribed medication: involve the client's doctor or prescriber.
• Signs of coercion, isolation from family and friends, escalating costs or secrecy: discuss openly and consider safeguarding.
• A crisis or thoughts of suicide: follow your crisis protocol. In the US, call or text 988; in the UK and Ireland, Samaritans on 116 123.

Drawn automatically from the guide's own sections. Stay curious: neither endorse nor dismiss what the client values, and check anything that matters against the full guide and its sources. Not medical advice.